Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meclofenamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 13/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | GMNN | O75496 | 1/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | GAA | P10253 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.97 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meclofenamic Acid SCHEMBL1649454 | 1.00 | PTGS2 (0.97) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL30384019 | 1.00 | PTGS2 (0.97) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL4400214 | 0.99 | PTGS2 (1.00) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL1874563 | 0.99 | PTGS2 (1.00) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL3504 | 0.99 | PTGS2 (1.00) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL30241166 | 0.99 | PTGS2 (1.00) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL18171844 | 0.94 | PTGS2 (0.90) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL1462647 | 0.88 | PTGS2 (0.79) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL1538458 | 0.87 | PTGS2 (0.77) | PTGS2MEN1MAPK1KMT2AGMNN | |
| Meclofenamic Acid SCHEMBL8531474 | 0.87 | PTGS2 (0.77) | PTGS2MEN1MAPK1KMT2AGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137632-A1 | NONAQUEOUS PREPARATION FOR PERCUTANEOUS ABSORPTION | LEAD CHEMICAL CO., LTD. (JP) | 2026-05-21 | — | — | US | disclosed |
| EP-4656206-A1 | NON-AQUEOUS PERCUTANEOUSLY ABSORPTIVE FORMULATION | Lead Chemical Co., Ltd. (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-3856734-B1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025043297-A1 | METHOD OF TREATING MYOPIA | MCFADDEN SALLY (AU) | 2025-03-06 | — | — | WO | disclosed |
| CN-110573881-B | Method for determining interactions between biological cells | 艾克斯赛安西娅有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12065422-B2 | Reagents and process for direct C—H functionalization | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| US-12029717-B2 | Methods for treating brain metastasis | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-07-09 | — | — | US | disclosed |
| EP-3575791-B1 | BLOOD TREATMENT METHOD AND BLOOD COLLECTION TUBE | ARKRAY INC (JP) | 2024-01-10 | — | — | EP | disclosed |
| EP-3685832-B1 | METHODS FOR TREATING BRAIN METASTASIS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-11608322-B2 | Reagents and process for direct C—H functionalization | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-03-21 | — | — | US | disclosed |
| CN-110547288-B | Blood processing method and blood collection tube | 爱科来株式会社 | 2022-09-02 | — | — | CN | disclosed |
| US-20220105069-A1 | METHODS FOR TREATING BRAIN METASTASIS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | CFH, DOHH, CTSH | PTGS2 3723/4885PTGS1 3936/4885MEN1 2782/4885 |
| US-20220105069-A1 | METHODS FOR TREATING BRAIN METASTASIS | GJA1, GJB2, EPCAM | PTGS2 599/4885PTGS1 359/4885MEN1 894/4885 |
| US-11608322-B2 | Reagents and process for direct C—H functionalization | CFH, DOHH, CTSH | PTGS2 3850/4885PTGS1 4021/4885MEN1 2686/4885 |
| US-20260137632-A1 | NONAQUEOUS PREPARATION FOR PERCUTANEOUS ABSORPTION | PTGS1, PTGER1, MMP1 | PTGS2 12/4885PTGS1 1/4885MEN1 3365/4885 |
| US-12029717-B2 | Methods for treating brain metastasis | GJA1, GJB2, EPCAM | PTGS2 599/4885PTGS1 359/4885MEN1 894/4885 |
| US-12065422-B2 | Reagents and process for direct C—H functionalization | CFH, DOHH, CTSH | PTGS2 3850/4885PTGS1 4021/4885MEN1 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.